{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:48:44Z","timestamp":1789908524981,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["N.A"],"award-info":[{"award-number":["N.A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\/objectives<\/jats:title>\n                <jats:p>Multiple modes of administration are available for systemic lupus erythematosus (SLE) treatments. This study examined patient and physician characteristics associated with the choice of weekly subcutaneous (SC) injection or monthly intravenous (IV) infusion for an unspecified SLE treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a cross-sectional, US web-based survey using a direct elicitation, stated-preference methodology (HO-16-16706). Two hundred patients and 200 physicians were asked to choose between IV or SC administration in a hypothetical scenario. Pairwise and multivariate analyses estimated the odds ratio (OR) for the likelihood of choosing SC over IV for respondent characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among patients, taking non-steroidal anti-inflammatory drugs increased the likelihood of choosing SC injection (OR 3.884), whilst having SLE-related skin problems, a fear of needles or self-injection, and never needing help around the house decreased the likelihood (OR 0.28, 0.13, 0.12, respectively; all <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.05). Among physicians, &gt;\u200995% recommended SC injection for patients who live or work far from an infusion center, prefer SC administration, and never or rarely miss medication doses. Physician characteristics including age and treatment practice also influenced choice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patient and physician characteristics influence choice of SC versus IV therapy for SLE. These findings might inform shared decision-making, which could lead to improved patient outcomes.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Data regarding patient and physician preference for different modes of administration of SLE therapy are sparse.<\/jats:italic><jats:italic>\u2022 This cross-sectional<\/jats:italic>, <jats:italic>US web-based study showed that patient and physician characteristics influence choice of SC<\/jats:italic> versus <jats:italic>IV therapy for SLE.<\/jats:italic><jats:italic>\u2022 A degree of disconnect exists between how factors influence patients<\/jats:italic>\u2019 <jats:italic>choice and how those characteristics influence physicians<\/jats:italic>\u2019 <jats:italic>choice of SLE treatment mode of administration.<\/jats:italic><jats:italic>\u2022 The findings from this study might inform shared decision-making<\/jats:italic>, <jats:italic>which could improve alignment between treatment choice and patient preferences<\/jats:italic>, <jats:italic>treatment satisfaction<\/jats:italic>, <jats:italic>adherence<\/jats:italic>, <jats:italic>and improved patient outcomes.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-020-05226-w","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T12:02:32Z","timestamp":1593864152000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-2537","authenticated-orcid":false,"given":"Christopher F.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-937X","authenticated-orcid":false,"given":"Melody","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-3411","authenticated-orcid":false,"given":"Christine","family":"Poulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"5226_CR1","first-page":"423","volume":"112","author":"A Kuhn","year":"2015","unstructured":"Kuhn A, Bonsmann G, Anders H-J, Herzer P, Tenbrock K, Schneider M (2015) The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 112:423","journal-title":"Dtsch Arztebl Int"},{"key":"5226_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-1172-1-6","volume":"1","author":"JJ Manson","year":"2006","unstructured":"Manson JJ, Rahman A (2006) Systemic lupus erythematosus. Orphanet J Rare Dis 1:6. https:\/\/doi.org\/10.1186\/1750-1172-1-6","journal-title":"Orphanet J Rare Dis"},{"key":"5226_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11926-016-0562-3","volume":"18","author":"D Fernandez","year":"2016","unstructured":"Fernandez D, Kirou KA (2016) What causes lupus flares? Curr Rheumatol Rep 18:14. https:\/\/doi.org\/10.1007\/s11926-016-0562-3","journal-title":"Curr Rheumatol Rep"},{"key":"5226_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3111\/13696998.2013.778270","volume":"16","author":"C Garris","year":"2013","unstructured":"Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G (2013) Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 16:667\u2013677. https:\/\/doi.org\/10.3111\/13696998.2013.778270","journal-title":"J Med Econ"},{"key":"5226_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3111\/13696998.2013.802241","volume":"16","author":"H Kan","year":"2013","unstructured":"Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C (2013) A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ 16:793\u2013800. https:\/\/doi.org\/10.3111\/13696998.2013.802241","journal-title":"J Med Econ"},{"key":"5226_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","volume":"48","author":"SA Chambers","year":"2009","unstructured":"Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48:673\u2013675. https:\/\/doi.org\/10.1093\/rheumatology\/kep062","journal-title":"Rheumatology (Oxford)"},{"key":"5226_CR7","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/lupus-2017-000239","volume":"4","author":"Z Touma","year":"2017","unstructured":"Touma Z, Gladman DD (2017) Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med 4:e000239. https:\/\/doi.org\/10.1136\/lupus-2017-000239","journal-title":"Lupus Sci Med"},{"key":"5226_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/2040622310380100","volume":"1","author":"MB Amissah-Arthur","year":"2010","unstructured":"Amissah-Arthur MB, Gordon C (2010) Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis 1:163\u2013175. https:\/\/doi.org\/10.1177\/2040622310380100","journal-title":"Ther Adv Chronic Dis"},{"key":"5226_CR9","unstructured":"European Medicines Agency (EMA) (2016) Benlysta summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed 14 February 2019"},{"key":"5226_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1177\/0961203316642309","volume":"25","author":"SW Yapa","year":"2016","unstructured":"Yapa SW, Roth D, Gordon D, Struemper H (2016) Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus phase 3 program. Lupus 25:1448\u20131455. https:\/\/doi.org\/10.1177\/0961203316642309","journal-title":"Lupus"},{"key":"5226_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-017-0276-2","volume":"11","author":"E Dashiell-Aje","year":"2018","unstructured":"Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S (2018) Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient 11:119\u2013129. https:\/\/doi.org\/10.1007\/s40271-017-0276-2","journal-title":"Patient"},{"key":"5226_CR12","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253\u20133265","journal-title":"Arthritis Rheum"},{"key":"5226_CR13","unstructured":"Food and Drug Administration (2019) BENLYSTA (belimumab) prescribing information. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU-COMBINED.PDF. Accessed 11 September 2019"},{"key":"5226_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"5226_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/s0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731. https:\/\/doi.org\/10.1016\/s0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"5226_CR16","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind, placebo-controlled study. Arthritis Rheum 69:1016\u20131027","journal-title":"Arthritis Rheum"},{"key":"5226_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2147\/PPA.S227208","volume":"13","author":"J Mucke","year":"2019","unstructured":"Mucke J, Brinks R, Fischer-Betz R, Richter JG, Sander O, Schneider M, Chehab G (2019) Patient satisfaction and disease control in patients with systemic lupus erythematosus is not affected by switching from intravenous belimumab to subcutaneous injections. Patient Prefer Adherence 13:1889\u20131894. https:\/\/doi.org\/10.2147\/PPA.S227208","journal-title":"Patient Prefer Adherence"},{"key":"5226_CR18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrom K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"5226_CR19","doi-asserted-by":"crossref","unstructured":"Desroches S (2010) Shared decision making and chronic diseases. Allergy Asthma Clin Immunol 6(Suppl 4):A8","DOI":"10.1186\/1710-1492-6-S4-A8"},{"key":"5226_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/2046-4053-3-38","volume":"3","author":"MR Gionfriddo","year":"2014","unstructured":"Gionfriddo MR, Leppin AL, Brito JP, Leblanc A, Boehmer KR, Morris MA, Erwin PJ, Prokop LJ, Zeballos-Palacios CL, Malaga G, Miranda JJ, McLeod HM, Rodriguez-Gutierrez R, Huang R, Morey-Vargas OL, Murad MH, Montori VM (2014) A systematic review of shared decision making interventions in chronic conditions: a review protocol. Syst Rev 3:38. https:\/\/doi.org\/10.1186\/2046-4053-3-38","journal-title":"Syst Rev"},{"key":"5226_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12913-016-1603-3","volume":"16","author":"A Olomu","year":"2016","unstructured":"Olomu A, Hart-Davidson W, Luo Z, Kelly-Blake K, Holmes-Rovner M (2016) Implementing shared decision making in federally qualified health centers, a quasi-experimental design study: the Office-Guidelines Applied to Practice (Office-GAP) program. BMC Health Serv Res 16:334. https:\/\/doi.org\/10.1186\/s12913-016-1603-3","journal-title":"BMC Health Serv Res"},{"key":"5226_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/acr.22904","volume":"68","author":"H Qu","year":"2016","unstructured":"Qu H, Shewchuk RM, Alarcon G, Fraenkel L, Leong A, Dall'Era M, Yazdany J, Singh JA (2016) Mapping perceptions of lupus medication decision-making facilitators: the importance of patient context. Arthritis Care Res 68:1787\u20131794. https:\/\/doi.org\/10.1002\/acr.22904","journal-title":"Arthritis Care Res"},{"key":"5226_CR23","unstructured":"Yedimenko J, Hackenberger P, Sullivan E, Morris K, Meara A (2018) Effectiveness of shared decision making in systemic lupus erythematosus patients at OSU. Arthritis Rheum:70"},{"key":"5226_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-10-1","volume":"10","author":"PB Allen","year":"2010","unstructured":"Allen PB, Lindsay H, Tham TC (2010) How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 10:1. https:\/\/doi.org\/10.1186\/1471-230X-10-1","journal-title":"BMC Gastroenterol"},{"key":"5226_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/PPA.S107790","volume":"10","author":"SC Bolge","year":"2016","unstructured":"Bolge SC, Goren A, Brown D, Ginsberg S, Allen I (2016) Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Prefer Adherence 10:1079\u20131090. https:\/\/doi.org\/10.2147\/PPA.S107790","journal-title":"Patient Prefer Adherence"},{"key":"5226_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA (2008) Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6:1\u201314. https:\/\/doi.org\/10.1002\/msc.110","journal-title":"Musculoskeletal Care"},{"key":"5226_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","volume":"36","author":"M Desplats","year":"2017","unstructured":"Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395\u20131400. https:\/\/doi.org\/10.1007\/s10067-017-3587-8","journal-title":"Clin Rheumatol"},{"key":"5226_CR28","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.waojou.2019.100030","volume":"12","author":"P Santus","year":"2019","unstructured":"Santus P, Ferrando M, Baiardini I, Radovanovic D, Fattori A, Braido F (2019) Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: a cross-sectional observational survey study. World Allergy Organ J 12:100030. https:\/\/doi.org\/10.1016\/j.waojou.2019.100030","journal-title":"World Allergy Organ J"},{"key":"5226_CR29","doi-asserted-by":"publisher","unstructured":"Mehat P, Atiquzzaman M, Esdaile JM, AviNa-Zubieta A, De Vera MA (2017) Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 69:1706\u20131713. https:\/\/doi.org\/10.1002\/acr.23191","DOI":"10.1002\/acr.23191"},{"key":"5226_CR30","doi-asserted-by":"publisher","unstructured":"Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH (2015) Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 67:1712\u20131721. https:\/\/doi.org\/10.1002\/acr.22636","DOI":"10.1002\/acr.22636"},{"key":"5226_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/art.24236","volume":"61","author":"LJ Julian","year":"2009","unstructured":"Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, Katz P (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240\u2013246. https:\/\/doi.org\/10.1002\/art.24236","journal-title":"Arthritis Rheum"},{"key":"5226_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1191\/096120300678828785","volume":"9","author":"J Rojas-Serrano","year":"2000","unstructured":"Rojas-Serrano J, Cardiel MH (2000) Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9:601\u2013606. https:\/\/doi.org\/10.1191\/096120300678828785","journal-title":"Lupus"},{"key":"5226_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3122\/jabfm.2018.05.180009","volume":"31","author":"A Schoenthaler","year":"2018","unstructured":"Schoenthaler A, Rosenthal DM, Butler M, Jacobowitz L (2018) Medication adherence improvement similar for shared decision-making preference or longer patient-provider relationship. J Am Board Fam Med 31:752\u2013760. https:\/\/doi.org\/10.3122\/jabfm.2018.05.180009","journal-title":"J Am Board Fam Med"},{"key":"5226_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/art.11467","volume":"49","author":"MM Ward","year":"2003","unstructured":"Ward MM, Sundaramurthy S, Lotstein D, Bush TM, Neuwelt CM, Street RL Jr (2003) Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis Rheum 49:810\u2013818. https:\/\/doi.org\/10.1002\/art.11467","journal-title":"Arthritis Rheum"},{"key":"5226_CR35","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS, Petri M (2015) Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42:2092\u20132097. https:\/\/doi.org\/10.3899\/jrheum.150379","journal-title":"J Rheumatol"},{"key":"5226_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/2374373518770811","volume":"6","author":"M Falanga","year":"2019","unstructured":"Falanga M, Canzona A, Mazzoni D (2019) Preference for subcutaneous injection or intravenous infusion of biological therapy among Italian patients with SLE. J Patient Exp 6:41\u201345","journal-title":"J Patient Exp"},{"key":"5226_CR37","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.clinthera.2017.07.039","volume":"39","author":"K Pascoe","year":"2017","unstructured":"Pascoe K, Lobosco S, Bell D, Hoskin B, Chang DJ, Pobiner B, Ramachandran S (2017) Patient- and physician-reported satisfaction with systemic lupus erythematosus treatment in US clinical practice. Clin Ther 39:1811\u20131826. https:\/\/doi.org\/10.1016\/j.clinthera.2017.07.039","journal-title":"Clin Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05226-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05226-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05226-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T23:37:22Z","timestamp":1625355442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05226-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5226"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05226-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All physicians and patients included in this study provided consent and informed consent, respectively. This study was reviewed\/approved by an Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"CFB and MLee are employees of GSK and hold shares in the company.MLau was an employee at GSK at the time of study. He is currently employed at Takeda Pharmaceuticals USA, Inc.CP is an employee of RTI Health Solutions, which was contracted by GSK to design and implement the study described in the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}